We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
ESC 2024 - "The study met all the 10 endpoints", says Marianna Fontana. She explains what the primary and secondary endpoints were of the HELIOS-B study, in which the efffect of vutrisiran was evaluated in patients with ATTR-CM, who were on or off background therapy.
This video was recorded during the ESC Congress 2024 in London, UK.
Marianna Fontana is the Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, UK.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 30 August 2024
ESC 2024 - "The study met all the 10 endpoints", says Marianna Fontana. She explains what the primary and secondary endpoints were of the HELIOS-B study, in which the efffect of vutrisiran was evaluated in patients with ATTR-CM, who were on or off background therapy.
This video was recorded during the ESC Congress 2024 in London, UK.
Marianna Fontana is the Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, UK.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 30 August 2024
Stay current with the best on medical education
